Meridian Bioscience (NASDAQ:VIVO) issued an update on its FY 2019 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus estimate of $0.77. The company issued revenue guidance of $217.842-222.114 million, compared to the consensus revenue estimate of $217.65 million.Meridian Bioscience also updated its guidance to EPS.

VIVO opened at $19.72 on Friday. Meridian Bioscience has a fifty-two week low of $13.53 and a fifty-two week high of $19.84. The company has a debt-to-equity ratio of 0.27, a current ratio of 5.73 and a quick ratio of 3.89. The stock has a market cap of $719.87 million, a PE ratio of 26.65 and a beta of 0.54.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, November 8th. The company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.04. Meridian Bioscience had a return on equity of 16.97% and a net margin of 11.49%. The business had revenue of $213.60 million for the quarter, compared to the consensus estimate of $51.11 million. During the same period last year, the business earned $0.15 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. On average, research analysts forecast that Meridian Bioscience will post 0.77 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 30th. Investors of record on Monday, November 19th will be paid a $0.125 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date is Friday, November 16th. Meridian Bioscience’s payout ratio is 67.57%.

A number of research analysts recently weighed in on VIVO shares. BidaskClub raised Meridian Bioscience from a sell rating to a hold rating in a research note on Friday, August 24th. ValuEngine raised Meridian Bioscience from a hold rating to a buy rating in a research note on Monday, October 29th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $16.00.

In related news, Director John Mcilwraith acquired 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 24th. The shares were acquired at an average cost of $15.63 per share, with a total value of $31,260.00. Following the purchase, the director now owns 6,000 shares of the company’s stock, valued at $93,780. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Meridian Bioscience (VIVO) Releases FY 2019 Earnings Guidance” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

See Also: What are the components of an earnings report?

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with's FREE daily email newsletter.